DK2868660T3 - Anti-tumoreffekt-potentiator omfattende en imidazooxazin-forbindelse - Google Patents
Anti-tumoreffekt-potentiator omfattende en imidazooxazin-forbindelseInfo
- Publication number
- DK2868660T3 DK2868660T3 DK13813275.8T DK13813275T DK2868660T3 DK 2868660 T3 DK2868660 T3 DK 2868660T3 DK 13813275 T DK13813275 T DK 13813275T DK 2868660 T3 DK2868660 T3 DK 2868660T3
- Authority
- DK
- Denmark
- Prior art keywords
- group
- atom
- substituent
- alkoxy
- effect potentiator
- Prior art date
Links
- -1 IMIDAZOOXAZINE COMPOUND Chemical class 0.000 title abstract 2
- 230000000259 anti-tumor effect Effects 0.000 title abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000003277 amino group Chemical group 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012148850 | 2012-07-02 | ||
| JP2012215902 | 2012-09-28 | ||
| PCT/JP2013/068054 WO2014007217A1 (ja) | 2012-07-02 | 2013-07-01 | イミダゾオキサジン化合物による抗腫瘍効果増強剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2868660T3 true DK2868660T3 (da) | 2018-01-29 |
Family
ID=49881973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13813275.8T DK2868660T3 (da) | 2012-07-02 | 2013-07-01 | Anti-tumoreffekt-potentiator omfattende en imidazooxazin-forbindelse |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9375434B2 (da) |
| EP (1) | EP2868660B1 (da) |
| JP (1) | JP5855250B2 (da) |
| KR (2) | KR101671761B1 (da) |
| AU (1) | AU2013284570B2 (da) |
| DK (1) | DK2868660T3 (da) |
| ES (1) | ES2660215T3 (da) |
| HU (1) | HUE036188T2 (da) |
| NO (1) | NO2868660T3 (da) |
| PL (1) | PL2868660T3 (da) |
| PT (1) | PT2868660T (da) |
| RU (1) | RU2618423C2 (da) |
| TW (1) | TWI534149B (da) |
| WO (1) | WO2014007217A1 (da) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3543355T3 (da) * | 2013-06-20 | 2021-03-01 | Taiho Pharmaceutical Co Ltd | Fremgangsmåde til forudsigelse af terapeutisk effektivitet for pi3k/akt/mtor-hæmmer på basis af phlda1- eller pik3c2b-ekspression |
| US10124003B2 (en) | 2013-07-18 | 2018-11-13 | Taiho Pharmaceutical Co., Ltd. | Therapeutic agent for FGFR inhibitor-resistant cancer |
| PT3023100T (pt) | 2013-07-18 | 2019-05-29 | Taiho Pharmaceutical Co Ltd | Fármaco antitumoral para administração intermitente de inibidor de fgfr |
| JPWO2016136928A1 (ja) * | 2015-02-27 | 2017-08-31 | 大鵬薬品工業株式会社 | イミダゾオキサジンの結晶、当該結晶を含む医薬組成物、及び当該結晶の製造方法 |
| KR20220110859A (ko) | 2016-03-04 | 2022-08-09 | 다이호야쿠힌고교 가부시키가이샤 | 악성 종양 치료용 제제 및 조성물 |
| US11883404B2 (en) * | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| MX2020009762A (es) | 2018-03-19 | 2021-01-08 | Taiho Pharmaceutical Co Ltd | Composicion farmaceutica que incluye alquil sulfato de sodio. |
| MA56549A (fr) * | 2019-06-21 | 2022-04-27 | Taiho Pharmaceutical Co Ltd | Méthode de traitement d'une tumeur maligne |
| EP4143167B1 (en) | 2020-04-28 | 2024-05-15 | Basf Se | Pesticidal compounds |
| US20240122937A1 (en) * | 2021-02-01 | 2024-04-18 | Taiho Pharmaceutical Co., Ltd. | Treating cancer in patient with pten inactivating mutation |
| CN118302417A (zh) * | 2021-08-25 | 2024-07-05 | Ptc医疗公司 | Nlrp3抑制剂 |
| CN119912475B (zh) * | 2025-03-06 | 2026-01-06 | 复旦大学 | 用作tlr2拮抗剂的化合物或其衍生物及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0714908B8 (pt) | 2006-08-08 | 2021-05-25 | Chugai Pharmaceutical Co Ltd | derivados de pirimidina como inibidor de pi3k, composição farmacêutica e agente preventivo ou agente terapêutico de uma doença proliferativa que os compreende |
| AR064010A1 (es) | 2006-12-06 | 2009-03-04 | Merck & Co Inc | Inhibidores de la actividad de la akt |
| MX2010001745A (es) * | 2007-08-14 | 2010-03-10 | Bayer Schering Pharma Ag | Imidazoles fusionados para el tratamiento del cancer. |
| US9451809B2 (en) | 2008-05-29 | 2016-09-27 | Nike, Inc. | Article of footwear with a marking system |
| CA2726317A1 (en) * | 2008-06-03 | 2009-12-10 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| WO2010088177A1 (en) | 2009-02-02 | 2010-08-05 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| US8481503B2 (en) * | 2009-03-06 | 2013-07-09 | Merck Sharp & Dohme Corp. | Combination cancer therapy with an AKT inhibitor and other anticancer agents |
| US8614221B2 (en) | 2009-03-11 | 2013-12-24 | Merck Sharp & Dohme Corp. | Inhibitors of Akt activity |
| US8691825B2 (en) | 2009-04-01 | 2014-04-08 | Merck Sharp & Dohme Corp. | Inhibitors of AKT activity |
| US8772283B2 (en) | 2011-04-06 | 2014-07-08 | Taiho Pharmaceutical Co., Ltd. | Imidazo-oxazine compound or salt thereof |
-
2013
- 2013-07-01 EP EP13813275.8A patent/EP2868660B1/en active Active
- 2013-07-01 US US14/407,745 patent/US9375434B2/en active Active
- 2013-07-01 KR KR1020157001880A patent/KR101671761B1/ko active Active
- 2013-07-01 PL PL13813275T patent/PL2868660T3/pl unknown
- 2013-07-01 KR KR1020167030063A patent/KR20160128456A/ko not_active Withdrawn
- 2013-07-01 ES ES13813275.8T patent/ES2660215T3/es active Active
- 2013-07-01 DK DK13813275.8T patent/DK2868660T3/da active
- 2013-07-01 PT PT138132758T patent/PT2868660T/pt unknown
- 2013-07-01 TW TW102123523A patent/TWI534149B/zh active
- 2013-07-01 RU RU2015103151A patent/RU2618423C2/ru active
- 2013-07-01 JP JP2014523736A patent/JP5855250B2/ja active Active
- 2013-07-01 HU HUE13813275A patent/HUE036188T2/hu unknown
- 2013-07-01 NO NO13813275A patent/NO2868660T3/no unknown
- 2013-07-01 WO PCT/JP2013/068054 patent/WO2014007217A1/ja not_active Ceased
- 2013-07-01 AU AU2013284570A patent/AU2013284570B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013284570B2 (en) | 2016-04-14 |
| NO2868660T3 (da) | 2018-05-26 |
| AU2013284570A1 (en) | 2015-01-22 |
| PT2868660T (pt) | 2018-02-02 |
| PL2868660T3 (pl) | 2018-05-30 |
| TW201408671A (zh) | 2014-03-01 |
| EP2868660A4 (en) | 2016-03-23 |
| TWI534149B (zh) | 2016-05-21 |
| US20150164909A1 (en) | 2015-06-18 |
| ES2660215T3 (es) | 2018-03-21 |
| WO2014007217A1 (ja) | 2014-01-09 |
| JPWO2014007217A1 (ja) | 2016-06-02 |
| EP2868660B1 (en) | 2017-12-27 |
| KR20150023870A (ko) | 2015-03-05 |
| EP2868660A1 (en) | 2015-05-06 |
| US9375434B2 (en) | 2016-06-28 |
| KR101671761B1 (ko) | 2016-11-02 |
| RU2015103151A (ru) | 2016-08-20 |
| JP5855250B2 (ja) | 2016-02-09 |
| RU2618423C2 (ru) | 2017-05-03 |
| KR20160128456A (ko) | 2016-11-07 |
| HUE036188T2 (hu) | 2018-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2868660T3 (da) | Anti-tumoreffekt-potentiator omfattende en imidazooxazin-forbindelse | |
| WO2013100566A8 (en) | Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same | |
| PH12013501873A1 (en) | Novel imidazo-oxazine compound or salt thereof | |
| EA201390885A1 (ru) | Азаиндолы в качестве противовирусных агентов против респираторного синцитиального вируса | |
| PH12016501535A1 (en) | Uracil derivatives as axl and c-met kinase inhibitors | |
| EA201390884A1 (ru) | Азабензимидазолы в качестве противовирусных средств в отношении респираторного синцитиального вируса | |
| IN2015MN00405A (da) | ||
| PH12015502232A1 (en) | Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists | |
| MX2014011829A (es) | Compuestos de piridinilideno n-sustituidos y derivados para combatir plagas de animales. | |
| JO3261B1 (ar) | مشتق بيريدين أحادي الحلقة | |
| PH12013501809A1 (en) | Endoparasite control agent | |
| MX394360B (es) | Inhibidores de jak2 y alk2 y metodos para su uso. | |
| MX2014000452A (es) | Derivados de azabencimiazol que tiene actividad activadora de la proteina cinasa activada monofosfato de denosina (ampk). | |
| MY196172A (en) | Tricyclic Spiro Compound | |
| MX2012002528A (es) | Agente terapeutico para trastornos del estado de animo. | |
| EA201491525A1 (ru) | Спиро[2.4]гептаны для лечения инфекций, вызванных flaviviridae | |
| HK1203932A1 (en) | Heterocyclic amide derivatives as p2x7 receptor antagonists | |
| MX364207B (es) | Inhibidores de agrecanasa. | |
| PH12016500152A1 (en) | Novel triazine derivative | |
| IN2014MN02485A (da) | ||
| MX343077B (es) | Nuevo derivado de octahidrotienoquinolina, composicion farmaceutica que comprende el derivado, y uso de los mismos. | |
| PH12014500212A1 (en) | Pyrrolidine-3-ylacetic acid derivative | |
| AR092772A1 (es) | Derivado de 7-azaindol | |
| MX336430B (es) | Derivados de dihidrofurano-azetadina como agentes antiparasitarios. | |
| MX2012002529A (es) | Agente terapeutico para trastornos de ansiedad. |